A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages≥ 2 Years to < 12 Years) With Atopic Dermatitis ((TRuE-AD3)
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms TRuE-AD3
- Sponsors Incyte Corporation
- 17 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Mar 2024 Results of subgroup analysis ruxolitinib cream efficacy by previous medication history in children , presented at the American Academy of Dermatology annual Meeting 2024
- 12 Mar 2024 Results of subgroup analysis ruxolitinib cream efficacy by previous medication history in children, presented at the American Academy of Dermatology annual Meeting 2024